JPWO2023068325A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023068325A5 JPWO2023068325A5 JP2023508530A JP2023508530A JPWO2023068325A5 JP WO2023068325 A5 JPWO2023068325 A5 JP WO2023068325A5 JP 2023508530 A JP2023508530 A JP 2023508530A JP 2023508530 A JP2023508530 A JP 2023508530A JP WO2023068325 A5 JPWO2023068325 A5 JP WO2023068325A5
- Authority
- JP
- Japan
- Prior art keywords
- nitrogen
- cancer cells
- cancer
- agent according
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 19
- 201000011510 cancer Diseases 0.000 claims 19
- 239000002246 antineoplastic agent Substances 0.000 claims 15
- QJGQUHMNIGDVPM-OUBTZVSYSA-N nitrogen-15 Chemical compound [15N] QJGQUHMNIGDVPM-OUBTZVSYSA-N 0.000 claims 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 238000000034 method Methods 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000001678 irradiating effect Effects 0.000 claims 2
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical group NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 claims 1
- 229960002749 aminolevulinic acid Drugs 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims 1
- 229950005454 doxifluridine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- MREOOEFUTWFQOC-UHFFFAOYSA-M potassium;5-chloro-4-hydroxy-1h-pyridin-2-one;4,6-dioxo-1h-1,3,5-triazine-2-carboxylate;5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione Chemical compound [K+].OC1=CC(=O)NC=C1Cl.[O-]C(=O)C1=NC(=O)NC(=O)N1.O=C1NC(=O)C(F)=CN1C1OCCC1 MREOOEFUTWFQOC-UHFFFAOYSA-M 0.000 claims 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims 1
- 229960001674 tegafur Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021172003 | 2021-10-20 | ||
| JP2021172003 | 2021-10-20 | ||
| PCT/JP2022/039079 WO2023068325A1 (ja) | 2021-10-20 | 2022-10-20 | 抗ガン剤、抗ガン剤のプロドラッグ、体外でガン細胞を死滅させる方法、ガンの治療方法、及びガンの治療装置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2023068325A1 JPWO2023068325A1 (https=) | 2023-04-27 |
| JPWO2023068325A5 true JPWO2023068325A5 (https=) | 2023-09-21 |
| JP7455316B2 JP7455316B2 (ja) | 2024-03-26 |
Family
ID=86058319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023508530A Active JP7455316B2 (ja) | 2021-10-20 | 2022-10-20 | 抗ガン剤、抗ガン剤のプロドラッグ、体外でガン細胞を死滅させる方法、ガンの治療方法、及びガンの治療装置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240424103A1 (https=) |
| EP (1) | EP4420678A4 (https=) |
| JP (1) | JP7455316B2 (https=) |
| CN (1) | CN118159293A (https=) |
| WO (1) | WO2023068325A1 (https=) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59203663A (ja) | 1983-05-02 | 1984-11-17 | Matsushita Electric Ind Co Ltd | 霧化装置 |
| JPH1112197A (ja) * | 1997-06-18 | 1999-01-19 | Cosmo Sogo Kenkyusho:Kk | 悪性腫瘍診断剤及び治療剤 |
| JP2003096098A (ja) * | 2001-09-25 | 2003-04-03 | Nippon Sanso Corp | 安定同位体標識抗体及びその製造方法ならびにこれを用いた検出方法 |
| JP4520219B2 (ja) | 2004-05-28 | 2010-08-04 | 協和発酵バイオ株式会社 | ５−アミノレブリン酸の製造法 |
| JP4750638B2 (ja) * | 2006-07-19 | 2011-08-17 | 独立行政法人 日本原子力研究開発機構 | 粒子線治療装置 |
| JP5392752B2 (ja) | 2009-02-18 | 2014-01-22 | 独立行政法人産業技術総合研究所 | 超低炭素ステンレス鋼製フランジおよび継ぎ手並びに超低炭素ステンレス鋼製封止用弁 |
| JP6234064B2 (ja) * | 2012-05-23 | 2017-11-22 | キヤノン株式会社 | 重合体、前記重合体を用いた核磁気共鳴分析用または磁気共鳴イメージング用の造影剤、化合物、前記重合体を用いた核磁気共鳴分析方法および磁気共鳴イメージング方法 |
| JP2014177421A (ja) * | 2013-03-14 | 2014-09-25 | Univ Of Fukui | 陽子線治療用増感剤、及びそれを用いた陽子線治療法 |
| JP2016216404A (ja) * | 2015-05-22 | 2016-12-22 | 国立大学法人北海道大学 | 陽子線治療用増感剤および陽子線治療方法 |
| US10314551B2 (en) * | 2015-06-16 | 2019-06-11 | The Trustees Of Princeton University | Detector, three-dimensional direct positron imaging unit, and method to estimate the differential of the radiation dose provided to cancer cells and healthy tissues during hadrotherapy |
| US10821191B2 (en) * | 2015-09-22 | 2020-11-03 | Byondis B.V. | SYD985 treatment of T-DM1 refractory cancer patients |
| EP3266470A1 (en) * | 2016-07-06 | 2018-01-10 | Fyzikální ústav AV CR, v.v.i. | Device and method for imaging and enhanced proton-therapy treatment using nuclear reactions |
| WO2018025168A1 (en) * | 2016-08-03 | 2018-02-08 | Pfizer Inc. | Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates |
| EP3641783A4 (en) * | 2017-06-22 | 2021-03-10 | University Of Virginia Patent Foundation | Proton activated atomic medicine |
| US11771779B2 (en) * | 2018-01-26 | 2023-10-03 | Hadasit Medical Research Services & Development Limited | Non-metallic magnetic resonance contrast agent |
| CN114207127B (zh) * | 2019-08-09 | 2024-11-29 | 国立研究开发法人产业技术综合研究所 | 人工基因和基因变异方法 |
| CN112834680B (zh) * | 2020-12-31 | 2023-03-03 | 苏州海科医药技术有限公司 | 一种测定肿瘤患者血浆中替加氟、吉美嘧啶和5-氟尿嘧啶浓度的方法 |
-
2022
- 2022-10-20 US US18/702,620 patent/US20240424103A1/en active Pending
- 2022-10-20 CN CN202280070780.XA patent/CN118159293A/zh active Pending
- 2022-10-20 WO PCT/JP2022/039079 patent/WO2023068325A1/ja not_active Ceased
- 2022-10-20 JP JP2023508530A patent/JP7455316B2/ja active Active
- 2022-10-20 EP EP22883629.2A patent/EP4420678A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12527874B2 (en) | Bioorthogonal compositions | |
| Wang et al. | Cancer radiosensitizers | |
| JP2025163103A (ja) | 放射線および／または抗がん治療補助療法としてアデノシン二リン酸リボースの活用 | |
| JP5642892B2 (ja) | 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤 | |
| US10272096B2 (en) | Methods and systems of treating wounds | |
| JPWO2023068325A5 (https=) | ||
| US20250017927A1 (en) | Pharmaceutical composition and use thereof | |
| Ye et al. | Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC) | |
| US20070293485A1 (en) | Drug administration methods | |
| Raitano et al. | Exploratory rat toxicology and efficacy of the boron neutron capture therapy drug boronotyrosine in a mouse model of head and neck cancer | |
| CN117835977A (zh) | Tead抑制剂的给药方案 | |
| El‐Said et al. | Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation | |
| RU2853399C1 (ru) | Способ повышения эффективности радиотерапии солидных новообразований в эксперименте | |
| Siemann et al. | Increased therapeutic benefit through the addition of misonidazole to a nitrosourea-radiation combination | |
| JP7224057B2 (ja) | 一酸化窒素供与体を含む血液脳関門の透過性を増加させるのに使用するための組成物及びその用途 | |
| CN121464130A (zh) | 可通过辐射激活的化合物及其用途 | |
| JP2007326814A (ja) | 放射性治療に対して抵抗性を有する癌の治療法。 | |
| JP2015091766A (ja) | 癌治療支援システム | |
| Matera et al. | Applications of molecular photoswitches in chemical biology | |
| Okabe et al. | Bioequivalence studies of a generic formulation (sw651k) to the brand drug s-1 in tumor-bearing rat models | |
| JP2004357952A (ja) | 薬物のレーザーによる吸収促進における、照射条件の設定方法 | |
| Korokina et al. | PHARMACEUTICAL SCIENCES | |
| WO2006105507A2 (en) | Indoloquinone tumor radiation sensitization | |
| CN101460174A (zh) | 给药方法 |